CLARITY PHARMACEUTICALS LTD - Announcements

0.00%

$3.80

Market Cap $1.413B

Healthcare Biotechnology

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical... Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. LATEST: Race Oncology Accelerates Game-Changing Cancer Drug.

Announcements

Filter Results

All Price Sensitive Only

CU6	Cleansing Notice		28/11/23	595.3KB	Share
CU6	Application for quotation of securities - CU6		28/11/23	26.75KB	Share
CU6	Application for quotation of securities - CU6		28/11/23	26.81KB	Share
CU6	Results of Meeting		23/11/23	67.23KB	Share
CU6	2023 ESG Report		23/11/23	8.4MB	Share
CU6	Managing Director's Presentation to AGM		23/11/23	9.31MB	Share
CU6	2023 AGM Chair's Address to Shareholders		23/11/23	228.76KB	Share
CU6	Bell Potter Healthcare Conference Presentation	PRICE SENSITIVE	15/11/23	6.71MB	Share
CU6	Recruitment target achieved for Phase II SAR-Bombesin trial	PRICE SENSITIVE	07/11/23	254.17KB	Share
CU6	2023 Appendix 4G		03/11/23	1.01MB	Share
CU6	Notification regarding unquoted securities - CU6		01/11/23	29.55KB	Share
CU6	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/23	8.73MB	Share
CU6	Presentation for Wilsons Drug and Device Conference	PRICE SENSITIVE	27/10/23	4.49MB	Share
CU6	Clarity and PSI kick off SAR-bisPSMA Phase III		26/10/23	599.83KB	Share
CU6	Notice of Annual General Meeting/Proxy Form		20/10/23	4.25MB	Share
CU6	Notification of cessation of securities - CU6		12/10/23	23.11KB	Share
CU6	First patient treated with Cu-67 SAR-Bombesin	PRICE SENSITIVE	03/10/23	239.83KB	Share
CU6	Corporate Governance Statement		29/09/23	732.35KB	Share
CU6	Annual Report to shareholders		29/09/23	14.67MB	Share
CU6	Company Presentation E&P Small Cap Healthcare Conference	PRICE SENSITIVE	13/09/23	6.09MB	Share
CU6	BOP preliminary trial results presented at EANM 2023	PRICE SENSITIVE	13/09/23	555.42KB	Share
CU6	Revised Change in substantial holding		06/09/23	738.98KB	Share
CU6	Change in substantial holding		05/09/23	706.49KB	Share
CU6	Ceasing to be a substantial holder		05/09/23	212.52KB	Share
CU6	Application for quotation of securities - CU6		28/08/23	25.23KB	Share
CU6	Notification regarding unquoted securities - CU6		28/08/23	34.2KB	Share
CU6	First neuroblastoma participant treated in highest cohort	PRICE SENSITIVE	25/08/23	260.46KB	Share
CU6	First PC participant treated at the highest dose level	PRICE SENSITIVE	25/08/23	522KB	Share
CU6	Preliminary Final Report	PRICE SENSITIVE	24/08/23	4.54MB	Share
CU6	Release of Securities from Escrow		21/08/23	207.19KB	Share
CU6	Theranostic prostate cancer trial advances to cohort 3	PRICE SENSITIVE	10/08/23	550.48KB	Share
CU6	Clarity Bolsters Antibody Pre-Targeting with IP from MSK	PRICE SENSITIVE	07/08/23	360.74KB	Share
CU6	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/23	5.77MB	Share
CU6	Final Cohort opens for CL04 Paediatric Neuroblastoma trial	PRICE SENSITIVE	26/07/23	252.23KB	Share
CU6	Phase II SABRE prostate cancer trial reaches 50% recruitment	PRICE SENSITIVE	24/07/23	446.39KB	Share
CU6	Change of Director's Interest Notice		06/07/23	921.97KB	Share
CU6	Cleansing Notice		06/07/23	595.15KB	Share
CU6	Notification regarding unquoted securities - CU6		06/07/23	27.31KB	Share
CU6	Application for quotation of securities - CU6		06/07/23	26.84KB	Share
CU6	Notification of cessation of securities - CU6		05/07/23	22.74KB	Share
CU6	Positive Guidance from FDA on Phase 3 Prostate Cancer Trial	PRICE SENSITIVE	04/07/23	280.94KB	Share
CU6	Cleansing Notice		28/06/23	596.42KB	Share
CU6	Application for quotation of securities - CU6		28/06/23	26.79KB	Share
CU6	Clarity Establishes US Center of Excellence for Research	PRICE SENSITIVE	28/06/23	219.28KB	Share
CU6	Northstar Achieves Key Production Milestones	PRICE SENSITIVE	27/06/23	228.96KB	Share
CU6	Cleansing Notice		20/06/23	537.62KB	Share
CU6	Application for quotation of securities - CU6		20/06/23	26.79KB	Share
CU6	COMBAT theranostic prostate cancer trial commences in the US	PRICE SENSITIVE	20/06/23	336.7KB	Share
CU6	Clarity expands supply of Cu-64 for Phase III trials	PRICE SENSITIVE	14/06/23	280.67KB	Share
CU6	Presentation at Jefferies Healthcare Conference	PRICE SENSITIVE	13/06/23	2.45MB	Share
CU6	Recruitment complete for Phase II prostate cancer trial	PRICE SENSITIVE	07/06/23	492.68KB	Share
CU6	Clarity to present at ASCO and SNMMI 2023 Annual Meetings		26/05/23	237.87KB	Share
CU6	Notification regarding unquoted securities - CU6		25/05/23	30.04KB	Share
CU6	Theranostic prostate cancer trial advances to cohort 2	PRICE SENSITIVE	24/05/23	451.67KB	Share
CU6	Final Director's Interest Notice - O'Bryan Tear		16/05/23	441.75KB	Share
CU6	Initial Director's Interest Notice		02/05/23	321.35KB	Share
CU6	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	17.8MB	Share
CU6	Clarity Receives $6.7 million R&D Tax Incentive Refund	PRICE SENSITIVE	18/04/23	191.77KB	Share
CU6	Notification of cessation of securities - CU6		11/04/23	24.58KB	Share
CU6	Notification regarding unquoted securities - CU6		05/04/23	30.32KB	Share
CU6	Clarity update on NorthStar copper-67 production		04/04/23	198.03KB	Share
CU6	Cleansing Notice		28/03/23	248.18KB	Share
CU6	Application for quotation of securities - CU6		28/03/23	26.68KB	Share
CU6	Clarity Corporate Presentation	PRICE SENSITIVE	13/03/23	4.17MB	Share
CU6	Clarity confirms no supply interruptions		02/03/23	210.48KB	Share
CU6	World leading expert in copper-67 joins Clarity SAB		01/03/23	205KB	Share
CU6	Half Yearly Report and Accounts		28/02/23	9.15MB	Share
CU6	Appendix 4D	PRICE SENSITIVE	28/02/23	821.55KB	Share
CU6	Change of Director's Interest Notice - Biggin		21/02/23	311.42KB	Share
CU6	Cleansing Notice		21/02/23	248.29KB	Share
CU6	Notification regarding unquoted securities - CU6		21/02/23	27.27KB	Share
CU6	Application for quotation of securities - CU6		21/02/23	26.78KB	Share
CU6	50% recruitment milestone for NET diagnostic Phase II trial	PRICE SENSITIVE	16/02/23	235.9KB	Share
CU6	PROPELLER Trial Results	PRICE SENSITIVE	14/02/23	999.71KB	Share
CU6	Ceasing to be a substantial holder		13/02/23	822.87KB	Share
CU6	Diagnostic prostate cancer trial reaches recruitment target	PRICE SENSITIVE	09/02/23	218.97KB	Share
CU6	Application for quotation of securities - CU6		02/02/23	26.7KB	Share
CU6	Changes to Clarity Board of Directors		01/02/23	202.39KB	Share
CU6	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	6MB	Share
CU6	Notification regarding unquoted securities - CU6		30/01/23	30.34KB	Share
CU6	Positive topline results from SAR-bisPSMA diagnostic trial	PRICE SENSITIVE	14/12/22	738.29KB	Share
CU6	Cleansing Notice		13/12/22	182.32KB	Share
CU6	Application for quotation of securities - CU6		13/12/22	26.66KB	Share
CU6	Change of Director's Interest Notices - Taylor and Biggin		09/12/22	239.5KB	Share
CU6	Notification regarding unquoted securities - CU6		09/12/22	30.94KB	Share
CU6	Clarity Corporate Presentation & Webinar		02/12/22	1.57MB	Share
CU6	Clarity Corporate Presentation & Webinar		02/12/22	143.16KB	Share
CU6	Results of Meeting		24/11/22	67.08KB	Share
CU6	Managing Director's Presentation to AGM	PRICE SENSITIVE	24/11/22	2.1MB	Share
CU6	Chairman's Address to Shareholders	PRICE SENSITIVE	24/11/22	221.37KB	Share
CU6	ESG Report		23/11/22	11.32MB	Share
CU6	IND approval from the FDA for theranostic SAR-Bombesin trial	PRICE SENSITIVE	21/11/22	734.4KB	Share
CU6	Application for quotation of securities - CU6		18/11/22	26.72KB	Share
CU6	Clarity Presentation -Bell Potter Healthcare Conference 2022	PRICE SENSITIVE	09/11/22	2.73MB	Share
CU6	Notification regarding unquoted securities - CU6		03/11/22	29.41KB	Share
CU6	50% recruitment reached for Phase II prostate cancer trial	PRICE SENSITIVE	02/11/22	308.28KB	Share
CU6	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	9.18MB	Share
CU6	Corporate Presentation - Wilsons Drug and Device Conference	PRICE SENSITIVE	28/10/22	1.34MB	Share
CU6	50% recruitment milestone reached for prostate cancer trial	PRICE SENSITIVE	27/10/22	311.17KB	Share
CU6	Notice of Annual General Meeting/Proxy Form		25/10/22	1.55MB	Share

CU6 Cleansing Notice
28/11/23		595.3KB	Share
CU6 Application for quotation of securities - CU6
28/11/23		26.75KB	Share
CU6 Application for quotation of securities - CU6
28/11/23		26.81KB	Share
CU6 Results of Meeting
23/11/23		67.23KB	Share
CU6 2023 ESG Report
23/11/23		8.4MB	Share
CU6 Managing Director's Presentation to AGM
23/11/23		9.31MB	Share
CU6 2023 AGM Chair's Address to Shareholders
23/11/23		228.76KB	Share
CU6 Bell Potter Healthcare Conference Presentation
15/11/23	PRICE SENSITIVE	6.71MB	Share
CU6 Recruitment target achieved for Phase II SAR-Bombesin trial
07/11/23	PRICE SENSITIVE	254.17KB	Share
CU6 2023 Appendix 4G
03/11/23		1.01MB	Share
CU6 Notification regarding unquoted securities - CU6
01/11/23		29.55KB	Share
CU6 Quarterly Activities/Appendix 4C Cash Flow Report
31/10/23	PRICE SENSITIVE	8.73MB	Share
CU6 Presentation for Wilsons Drug and Device Conference
27/10/23	PRICE SENSITIVE	4.49MB	Share
CU6 Clarity and PSI kick off SAR-bisPSMA Phase III
26/10/23		599.83KB	Share
CU6 Notice of Annual General Meeting/Proxy Form
20/10/23		4.25MB	Share
CU6 Notification of cessation of securities - CU6
12/10/23		23.11KB	Share
CU6 First patient treated with Cu-67 SAR-Bombesin
03/10/23	PRICE SENSITIVE	239.83KB	Share
CU6 Corporate Governance Statement
29/09/23		732.35KB	Share
CU6 Annual Report to shareholders
29/09/23		14.67MB	Share
CU6 Company Presentation E&P Small Cap Healthcare Conference
13/09/23	PRICE SENSITIVE	6.09MB	Share
CU6 BOP preliminary trial results presented at EANM 2023
13/09/23	PRICE SENSITIVE	555.42KB	Share
CU6 Revised Change in substantial holding
06/09/23		738.98KB	Share
CU6 Change in substantial holding
05/09/23		706.49KB	Share
CU6 Ceasing to be a substantial holder
05/09/23		212.52KB	Share
CU6 Application for quotation of securities - CU6
28/08/23		25.23KB	Share
CU6 Notification regarding unquoted securities - CU6
28/08/23		34.2KB	Share
CU6 First neuroblastoma participant treated in highest cohort
25/08/23	PRICE SENSITIVE	260.46KB	Share
CU6 First PC participant treated at the highest dose level
25/08/23	PRICE SENSITIVE	522KB	Share
CU6 Preliminary Final Report
24/08/23	PRICE SENSITIVE	4.54MB	Share
CU6 Release of Securities from Escrow
21/08/23		207.19KB	Share
CU6 Theranostic prostate cancer trial advances to cohort 3
10/08/23	PRICE SENSITIVE	550.48KB	Share
CU6 Clarity Bolsters Antibody Pre-Targeting with IP from MSK
07/08/23	PRICE SENSITIVE	360.74KB	Share
CU6 Quarterly Activities/Appendix 4C Cash Flow Report
31/07/23	PRICE SENSITIVE	5.77MB	Share
CU6 Final Cohort opens for CL04 Paediatric Neuroblastoma trial
26/07/23	PRICE SENSITIVE	252.23KB	Share
CU6 Phase II SABRE prostate cancer trial reaches 50% recruitment
24/07/23	PRICE SENSITIVE	446.39KB	Share
CU6 Change of Director's Interest Notice
06/07/23		921.97KB	Share
CU6 Cleansing Notice
06/07/23		595.15KB	Share
CU6 Notification regarding unquoted securities - CU6
06/07/23		27.31KB	Share
CU6 Application for quotation of securities - CU6
06/07/23		26.84KB	Share
CU6 Notification of cessation of securities - CU6
05/07/23		22.74KB	Share
CU6 Positive Guidance from FDA on Phase 3 Prostate Cancer Trial
04/07/23	PRICE SENSITIVE	280.94KB	Share
CU6 Cleansing Notice
28/06/23		596.42KB	Share
CU6 Application for quotation of securities - CU6
28/06/23		26.79KB	Share
CU6 Clarity Establishes US Center of Excellence for Research
28/06/23	PRICE SENSITIVE	219.28KB	Share
CU6 Northstar Achieves Key Production Milestones
27/06/23	PRICE SENSITIVE	228.96KB	Share
CU6 Cleansing Notice
20/06/23		537.62KB	Share
CU6 Application for quotation of securities - CU6
20/06/23		26.79KB	Share
CU6 COMBAT theranostic prostate cancer trial commences in the US
20/06/23	PRICE SENSITIVE	336.7KB	Share
CU6 Clarity expands supply of Cu-64 for Phase III trials
14/06/23	PRICE SENSITIVE	280.67KB	Share
CU6 Presentation at Jefferies Healthcare Conference
13/06/23	PRICE SENSITIVE	2.45MB	Share
CU6 Recruitment complete for Phase II prostate cancer trial
07/06/23	PRICE SENSITIVE	492.68KB	Share
CU6 Clarity to present at ASCO and SNMMI 2023 Annual Meetings
26/05/23		237.87KB	Share
CU6 Notification regarding unquoted securities - CU6
25/05/23		30.04KB	Share
CU6 Theranostic prostate cancer trial advances to cohort 2
24/05/23	PRICE SENSITIVE	451.67KB	Share
CU6 Final Director's Interest Notice - O'Bryan Tear
16/05/23		441.75KB	Share
CU6 Initial Director's Interest Notice
02/05/23		321.35KB	Share
CU6 Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	17.8MB	Share
CU6 Clarity Receives $6.7 million R&D Tax Incentive Refund
18/04/23	PRICE SENSITIVE	191.77KB	Share
CU6 Notification of cessation of securities - CU6
11/04/23		24.58KB	Share
CU6 Notification regarding unquoted securities - CU6
05/04/23		30.32KB	Share
CU6 Clarity update on NorthStar copper-67 production
04/04/23		198.03KB	Share
CU6 Cleansing Notice
28/03/23		248.18KB	Share
CU6 Application for quotation of securities - CU6
28/03/23		26.68KB	Share
CU6 Clarity Corporate Presentation
13/03/23	PRICE SENSITIVE	4.17MB	Share
CU6 Clarity confirms no supply interruptions
02/03/23		210.48KB	Share
CU6 World leading expert in copper-67 joins Clarity SAB
01/03/23		205KB	Share
CU6 Half Yearly Report and Accounts
28/02/23		9.15MB	Share
CU6 Appendix 4D
28/02/23	PRICE SENSITIVE	821.55KB	Share
CU6 Change of Director's Interest Notice - Biggin
21/02/23		311.42KB	Share
CU6 Cleansing Notice
21/02/23		248.29KB	Share
CU6 Notification regarding unquoted securities - CU6
21/02/23		27.27KB	Share
CU6 Application for quotation of securities - CU6
21/02/23		26.78KB	Share
CU6 50% recruitment milestone for NET diagnostic Phase II trial
16/02/23	PRICE SENSITIVE	235.9KB	Share
CU6 PROPELLER Trial Results
14/02/23	PRICE SENSITIVE	999.71KB	Share
CU6 Ceasing to be a substantial holder
13/02/23		822.87KB	Share
CU6 Diagnostic prostate cancer trial reaches recruitment target
09/02/23	PRICE SENSITIVE	218.97KB	Share
CU6 Application for quotation of securities - CU6
02/02/23		26.7KB	Share
CU6 Changes to Clarity Board of Directors
01/02/23		202.39KB	Share
CU6 Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	6MB	Share
CU6 Notification regarding unquoted securities - CU6
30/01/23		30.34KB	Share
CU6 Positive topline results from SAR-bisPSMA diagnostic trial
14/12/22	PRICE SENSITIVE	738.29KB	Share
CU6 Cleansing Notice
13/12/22		182.32KB	Share
CU6 Application for quotation of securities - CU6
13/12/22		26.66KB	Share
CU6 Change of Director's Interest Notices - Taylor and Biggin
09/12/22		239.5KB	Share
CU6 Notification regarding unquoted securities - CU6
09/12/22		30.94KB	Share
CU6 Clarity Corporate Presentation & Webinar
02/12/22		1.57MB	Share
CU6 Clarity Corporate Presentation & Webinar
02/12/22		143.16KB	Share
CU6 Results of Meeting
24/11/22		67.08KB	Share
CU6 Managing Director's Presentation to AGM
24/11/22	PRICE SENSITIVE	2.1MB	Share
CU6 Chairman's Address to Shareholders
24/11/22	PRICE SENSITIVE	221.37KB	Share
CU6 ESG Report
23/11/22		11.32MB	Share
CU6 IND approval from the FDA for theranostic SAR-Bombesin trial
21/11/22	PRICE SENSITIVE	734.4KB	Share
CU6 Application for quotation of securities - CU6
18/11/22		26.72KB	Share
CU6 Clarity Presentation -Bell Potter Healthcare Conference 2022
09/11/22	PRICE SENSITIVE	2.73MB	Share
CU6 Notification regarding unquoted securities - CU6
03/11/22		29.41KB	Share
CU6 50% recruitment reached for Phase II prostate cancer trial
02/11/22	PRICE SENSITIVE	308.28KB	Share
CU6 Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	9.18MB	Share
CU6 Corporate Presentation - Wilsons Drug and Device Conference
28/10/22	PRICE SENSITIVE	1.34MB	Share
CU6 50% recruitment milestone reached for prostate cancer trial
27/10/22	PRICE SENSITIVE	311.17KB	Share
CU6 Notice of Annual General Meeting/Proxy Form
25/10/22		1.55MB	Share

REFRESH

First 2 3 4

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $3.80		Change 0.000(0.00%)		Mkt cap ! $1.413B

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	1000	$4.00

Sellers (Offers)

Price($)	Vol.	No.
$3.57	9	1

View Market Depth

No.	Vol.	Price($)
3	1739	3.890
4	2673	3.880
5	12393	3.870
8	13186	3.860
7	13119	3.850

Price($)	Vol.	No.
3.900	3810	4
3.910	5087	5
3.920	9039	6
3.930	26746	7
3.940	16503	6

Last trade - 09.45am 11/08/2025 (20 minute delay)


Last $3.90		Change 0.000 ( 1.45 %)
Open	High	Low	Volume
$3.89	$3.98	$3.89	16494
Last updated 10.05am 11/08/2025 ?

CU6 (ASX) Chart

CLARITY PHARMACEUTICALS LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories